PVLA
Palvella Therapeutics, Inc.NASDAQHealthcare$123.46+2.56%ClosedMarket Cap: $1.46B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
48.19
P/S
0.00
EV/EBITDA
-52.93
DCF Value
$4.71
FCF Yield
-1.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-98.1%
ROA
-70.0%
ROIC
-79.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-11.3M | $-12.7M | $-1.08 | — |
| FY 2025 | $0.00 | NaN% | $-38.6M | $-41.7M | $-3.71 | — |
| Q3 2025 | $0.00 | NaN% | $-10.2M | $-11.3M | $-1.03 | — |
| Q2 2025 | $0.00 | NaN% | $-9.3M | $-9.5M | $-0.86 | — |
| Q1 2025 | $0.00 | NaN% | $-7.9M | $-8.2M | $-3.68 | — |
| Q4 2024 | $0.00 | NaN% | $-4.4M | $-4.0M | $-0.88 | — |
| FY 2024 | $0.00 | NaN% | $-14.1M | $-17.4M | $-7.83 | — |
| Q3 2024 | $0.00 | NaN% | $-5.1M | $-6.8M | $-2.19 | — |
| Q2 2024 | $0.00 | NaN% | $-2.9M | $-4.2M | $-3.37 | — |
| Q1 2024 | $0.00 | NaN% | $-1.8M | $-2.5M | $-2.00 | — |
| Q4 2023 | $1.3M | 100.0% | $-5.5M | $-4.6M | $-3.71 | — |
| FY 2023 | $0.00 | NaN% | $-11.9M | $18.7M | $14.74 | — |